Prostate cancer remains one of the most common cancers affecting men in the United States, and researchers continue to study how early detection influences outcomes. One factor drawing renewed attention is participation in recommended screening, particularly as evidence accumulates about long-term risk patterns.

According to the American Cancer Society, about one in eight men will be diagnosed with prostate cancer during their lifetime. While many cases are slow-growing and highly treatable, the disease is still the second leading cause of cancer-related death among men, after lung cancer.

Researchers emphasize that the issue is not a single “dangerous behavior,” but rather consistent avoidance of screening and follow-up care, which can delay diagnosis until the disease is more advanced.

What the research shows

Long-term data from the European Randomised Study of Screening for Prostate Cancer (ERSPC)—the largest prostate cancer screening study to date—has followed men across seven European countries for more than 20 years.

The study suggests that PSA (prostate-specific antigen) testing can help detect prostate cancer earlier and is associated with a reduction in prostate cancer mortality at the population level. Overall, men invited to regular screening showed about a 20 percent lower risk of dying from prostate cancer compared to those not screened.

A closer analysis looked specifically at attendance patterns. Researchers examined data from more than 72,000 men and found a clear difference between those who consistently attended screening appointments and those who declined them.

• Men who skipped every screening invitation had a substantially higher risk of dying from prostate cancer.

• Men who participated in screening showed a notably lower risk over time.

Lead author Renée Leenen, MD, PhD, noted that men who avoid screening may also be less likely to engage in preventive healthcare more broadly, which can compound risk.

“This may reflect a general pattern of care avoidance,” she explained, rather than the screening decision alone.

Important context on screening

Medical experts stress that prostate cancer screening is not one-size-fits-all. PSA testing can detect cancers early, but it can also identify slow-growing tumors that may never cause harm. For that reason, many health organizations recommend shared decision-making—a conversation between a patient and doctor that considers age, family history, race, overall health, and personal values.

Researchers involved in the ERSPC emphasize that improving outcomes depends not just on offering screening, but on informed participation, appropriate follow-up, and avoiding unnecessary treatment.

The findings are scheduled to be presented at the European Association of Urology Congress, where experts will continue discussing how to design screening programs that balance early detection with minimizing harm.

The takeaway

Prostate cancer risk is shaped by many factors, including age, genetics, and access to care. Screening does not prevent cancer, but evidence suggests that regular engagement with healthcare—rather than avoidance—can reduce the likelihood of dying from the disease.

Men are encouraged to speak with a healthcare professional about whether and when screening is appropriate for them, rather than avoiding the conversation altogether.

Early awareness, informed choices, and ongoing medical care remain the most reliable tools for navigating prostate cancer risk—without fear, exaggeration, or false certainty.